191 related articles for article (PubMed ID: 25104468)
1. A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.
Vaitaitis GM; Olmstead MH; Waid DM; Carter JR; Wagner DH
Diabetologia; 2014 Nov; 57(11):2366-73. PubMed ID: 25104468
[TBL] [Abstract][Full Text] [Related]
2. Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY
Vaitaitis GM; Wagner DH
J Biol Chem; 2023 May; 299(5):104625. PubMed ID: 36944397
[TBL] [Abstract][Full Text] [Related]
3. CD40-targeting KGYY
Bojadzic D; Buchwald P
Diabetologia; 2019 Nov; 62(11):2158-2160. PubMed ID: 31501919
[No Abstract] [Full Text] [Related]
4. CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity.
Vaitaitis GM; Wagner DH
Mol Immunol; 2010 Aug; 47(14):2303-13. PubMed ID: 20646763
[TBL] [Abstract][Full Text] [Related]
5. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation.
Molano RD; Berney T; Li H; Cattan P; Pileggi A; Vizzardelli C; Kenyon NS; Ricordi C; Burkly LC; Inverardi L
Diabetes; 2001 Feb; 50(2):270-6. PubMed ID: 11272136
[TBL] [Abstract][Full Text] [Related]
6. A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.
Vaitaitis GM; Yussman MG; Wagner DH
J Neuroimmunol; 2019 Jul; 332():8-15. PubMed ID: 30925295
[TBL] [Abstract][Full Text] [Related]
7. CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.
Vaitaitis GM; Waid DM; Yussman MG; Wagner DH
Immunology; 2017 Oct; 152(2):243-254. PubMed ID: 28542921
[TBL] [Abstract][Full Text] [Related]
8. High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity.
Vaitaitis GM; Wagner DH
PLoS One; 2008 Apr; 3(4):e2076. PubMed ID: 18446238
[TBL] [Abstract][Full Text] [Related]
9. CD40 and autoimmunity: the dark side of a great activator.
Peters AL; Stunz LL; Bishop GA
Semin Immunol; 2009 Oct; 21(5):293-300. PubMed ID: 19595612
[TBL] [Abstract][Full Text] [Related]
10. T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes.
Baker RL; Mallevaey T; Gapin L; Haskins K
Eur J Immunol; 2012 Mar; 42(3):672-80. PubMed ID: 22488364
[TBL] [Abstract][Full Text] [Related]
11. An alternative role for Foxp3 as an effector T cell regulator controlled through CD40.
Vaitaitis GM; Carter JR; Waid DM; Olmstead MH; Wagner DH
J Immunol; 2013 Jul; 191(2):717-25. PubMed ID: 23776180
[TBL] [Abstract][Full Text] [Related]
12. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity.
Baker RL; Wagner DH; Haskins K
J Autoimmun; 2008 Dec; 31(4):385-92. PubMed ID: 18951762
[TBL] [Abstract][Full Text] [Related]
13. Islet allograft rejection in nonobese diabetic mice involves the common gamma-chain and CD28/CD154-dependent and -independent mechanisms.
Demirci G; Strom TB; Li XC
J Immunol; 2003 Oct; 171(7):3878-85. PubMed ID: 14500690
[TBL] [Abstract][Full Text] [Related]
14. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice.
Arefanian H; Tredget EB; Rajotte RV; Korbutt GS; Gill RG; Rayat GR
Cell Transplant; 2007; 16(8):787-98. PubMed ID: 18087999
[TBL] [Abstract][Full Text] [Related]
15. Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects.
Margolles-Clark E; Jacques-Silva MC; Ganesan L; Umland O; Kenyon NS; Ricordi C; Berggren PO; Buchwald P
Biochem Pharmacol; 2009 Apr; 77(7):1236-45. PubMed ID: 19283894
[TBL] [Abstract][Full Text] [Related]
16. CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter].
Vaitaitis GM; Olmstead MH; Waid DM; Carter JR; Wagner DH
Diabetologia; 2019 Sep; 62(9):1730-1731. PubMed ID: 31286154
[No Abstract] [Full Text] [Related]
17. Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.
Portillo JA; Greene JA; Schwartz I; Subauste MC; Subauste CS
Immunology; 2015 Jan; 144(1):21-33. PubMed ID: 25051892
[TBL] [Abstract][Full Text] [Related]
18. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity.
Vaitaitis GM; Wagner DH
PLoS One; 2012; 7(6):e38708. PubMed ID: 22685601
[TBL] [Abstract][Full Text] [Related]
19. [Involvement of CD40-CD154 interaction in immunopathogenesis of collagen diseases and its application to a novel therapeutic strategy].
Harigai M
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Dec; 27(6):379-88. PubMed ID: 15678891
[TBL] [Abstract][Full Text] [Related]
20. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse.
Nanji SA; Hancock WW; Luo B; Schur CD; Pawlick RL; Zhu LF; Anderson CC; Shapiro AM
Diabetes; 2006 Jan; 55(1):27-33. PubMed ID: 16380473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
